- Home
- IONS vs ACHR Comparison
IONS vs ACHR Comparison
Compare IONS & ACHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ACHR
- Stock Information
- Founded
- IONS 1989
- ACHR 2018
- Country
- IONS United States
- ACHR United States
- Employees
- IONS N/A
- ACHR N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ACHR Aerospace
- Sector
- IONS Health Care
- ACHR Industrials
- Exchange
- IONS Nasdaq
- ACHR Nasdaq
- Market Cap
- IONS 6.0B
- ACHR 4.8B
- IPO Year
- IONS 1991
- ACHR N/A
- Fundamental
- Price
- IONS $32.32
- ACHR $9.13
- Analyst Decision
- IONS Buy
- ACHR Strong Buy
- Analyst Count
- IONS 19
- ACHR 9
- Target Price
- IONS $61.24
- ACHR $11.33
- AVG Volume (30 Days)
- IONS 1.7M
- ACHR 32.8M
- Earning Date
- IONS 02-19-2025
- ACHR 02-27-2025
- Dividend Yield
- IONS N/A
- ACHR N/A
- EPS Growth
- IONS N/A
- ACHR N/A
- EPS
- IONS N/A
- ACHR N/A
- Revenue
- IONS $705,000,000.00
- ACHR N/A
- Revenue This Year
- IONS N/A
- ACHR N/A
- Revenue Next Year
- IONS $10.08
- ACHR $2,607.26
- P/E Ratio
- IONS N/A
- ACHR N/A
- Revenue Growth
- IONS N/A
- ACHR N/A
- 52 Week Low
- IONS $30.23
- ACHR $2.82
- 52 Week High
- IONS $52.34
- ACHR $12.48
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- ACHR 46.55
- Support Level
- IONS $30.86
- ACHR $9.13
- Resistance Level
- IONS $34.74
- ACHR $11.84
- Average True Range (ATR)
- IONS 1.35
- ACHR 0.92
- MACD
- IONS 0.18
- ACHR 0.00
- Stochastic Oscillator
- IONS 46.34
- ACHR 14.89
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.